High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
55.52M
+19.56%
-0.202
-6.68%
60.68M
+27.86%
-0.185
-18.72%
59.54M
+13.53%
-0.170
-15%
Estimates Revision
The market is revising No Change the revenue expectations for Adaptive Biotechnologies Corporation (ADPT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 43.81%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+43.81%
In Past 3 Month
5 Analyst Rating
0Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
0Current: 13.000
Low
11.00
Averages
13.00
High
15.00
0Current: 13.000
Low
11.00
Averages
13.00
High
15.00
JPMorgan
Rachel Vatnsdal
Overweight
maintain
$10 -> $14
2025-08-06
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$10 -> $14
2025-08-06
maintain
Overweight
Reason
JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $14 from $10 and keeps an Overweight rating on the shares following the Q2 report. The firm believes momentum in the minimal residual disease business positions Adaptive for a strong back half of the year.
TD Cowen
Buy
maintain
$13 -> $15
2025-08-06
Reason
TD Cowen
Price Target
$13 -> $15
2025-08-06
maintain
Buy
Reason
TD Cowen raised the firm's price target on Adaptive Biotechnologies to $15 from $13 and keeps a Buy rating on the shares. The firm said they posted good results and noted guidance was raised and still see room for upside.
Piper Sandler
Overweight
maintain
$13 -> $15
2025-08-06
Reason
Piper Sandler
Price Target
$13 -> $15
2025-08-06
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Adaptive Biotechnologies to $15 from $13 and keeps an Overweight rating on the shares. The firm notes Adaptive Biotechnologies achieved significant volume acceleration in its MRD business, and Piper believes a go-forward 30% revenue growth rate is achievable for multiple quarters, particularly as key drivers like EMR integrations gain further traction. This, coupled with continued ASP expansion, positions the company to drive revenue growth in the top quartile of Piper's coverage group.
BTIG
Buy
maintain
$11 -> $13
2025-07-29
Reason
BTIG
Price Target
$11 -> $13
2025-07-29
maintain
Buy
Reason
BTIG raised the firm's price target on Adaptive Biotechnologies to $13 from $11 and keeps a Buy rating on the shares. ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Craig-Hallum
John Wilkin
initiated
$15
2025-06-19
Reason
Craig-Hallum
John Wilkin
Price Target
$15
2025-06-19
initiated
Reason
Craig-Hallum analyst John Wilkin initiated coverage of Adaptive Biotechnologies with a Buy rating and $15 price target.
Goldman Sachs
Salveen Richter
Hold
to
Strong Buy
Upgrades
$8 → $9
2025-03-21
Reason
Goldman Sachs
Salveen Richter
Price Target
$8 → $9
2025-03-21
Upgrades
Hold
to
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Adaptive Biotechnologies Corp (ADPT.O) is -18.35, compared to its 5-year average forward P/E of -12.74. For a more detailed relative valuation and DCF analysis to assess Adaptive Biotechnologies Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-12.74
Current PE
-18.35
Overvalued PE
-0.52
Undervalued PE
-24.96
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-17.45
Current EV/EBITDA
-74.15
Overvalued EV/EBITDA
-1.79
Undervalued EV/EBITDA
-33.11
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
14.51
Current PS
7.54
Overvalued PS
30.39
Undervalued PS
-1.37
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 176.86% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ADPT News & Events
Events Timeline
(ET)
2025-08-05
16:54:45
Adaptive Biotechnologies reports Q2 EPS (17c), consensus (24c)
2025-07-01 (ET)
2025-07-01
07:36:10
Adaptive, Flatiron Health integrates clonoSEQ MRD testing into OncoEMR
2025-05-30 (ET)
2025-05-30
07:35:34
Adaptive Biotechnologies highlights new data at ASCO Meeting, EHA Congress
Sign Up For More Events
Sign Up For More Events
News
Preview
4.0
08-08NASDAQ.COMAdaptive Biotechnologies Reaches Analyst Target Price
Preview
4.0
08-07BenzingaJP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $14
Preview
9.5
08-07NASDAQ.COMWhy Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday
Sign Up For More News
People Also Watch
FAQ
What is Adaptive Biotechnologies Corp (ADPT) stock price today?
What is Adaptive Biotechnologies Corp (ADPT)'s business?
What is the price predicton of ADPT Stock?
What is Adaptive Biotechnologies Corp (ADPT)'s revenue for the last quarter?
What is Adaptive Biotechnologies Corp (ADPT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Adaptive Biotechnologies Corp (ADPT)'s fundamentals?
How many employees does Adaptive Biotechnologies Corp (ADPT). have?